Malabsorption Syndrome Market Research Report– Global Forecast till 2023

Malabsorption Syndrome Market Trends And Share Analysis By Diagnosis (Tests, Imaging), Causative Diseases (Lactose Intolerance, Sprue, Cystic Fibrosis), Treatment (Gluten-Free Diet, Antidiarrheal Agents, Anti-Inflammatory Drugs), End User – Global Forecast Till 2023

ID: MRFR/Pharma/4014-HCR | February 2021 | Region: Global | 85 pages

Market Scenario:


Global Malabsorption Syndrome Market is expected to grow at a CAGR of 11.0% during the forecast period of 2017-2023Malabsorption syndrome is the poor absorption of fat, vitamins, carbohydrate, protein, and other nutrients from the intestinal tract into the bloodstream. The possible major causes of malabsorption syndrome are prolonged use of antibiotics, Celiac disease, Cystic fibrosis, Crohn’s disease, lactose intolerance, parasitic diseases, diseases of the gallbladder or liver, and intestinal inflammation.


It is noted that rising cases of causative diseases such as celiac disease, and others is the key factor driving the malabsorption syndrome market. Celiac disease is a serious autoimmune disorder, and is estimated to affect 1 in 100 people worldwide, suggested by Celiac Disease Foundation.


Various other factors such as unmet medical needs, increasing government assistance, rising healthcare expenditure in the developed countries, improving regulatory framework, increasing adoption rate, and rising funding and reimbursement policies are continuously contributing to the growth of the global malabsorption syndrome market.


Despite these drivers, there are some issues associated with malabsorption syndrome market. The side effects of drugs and other therapeutic agents, infections, lack of awareness in the developing countries, and poor healthcare system in low and middle-income countries, may hinder the growth of the market.


Intended Audience



  • Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Government Research Institute

  • Academic Institutes and Universities

  • Research Methodology


malabsorption

Sources: Annual reports, Press release, White paper, and Company presentation


Segmentation:


The global malabsorption syndrome market is segmented on the basis of diagnosis, causative diseases, treatment, and end user.


On the basis of the diagnosis, the market is classified as hematologic tests, imaging studies, and other tests. The imaging studies segment is classified as CT scan, magnetic resonance cholangiopancreatography (MRCP), endoscopic retrograde cholangiopancreatogram (ERCP), and abdominal X-ray. The other tests segment is classified as test of fat malabsorption, D-xylose test, tests of carbohydrate absorption, test of bile salt absorption, schilling test, and C-D-xylose breath test.


On the basis of the causative diseases, the market is classified as lactose intolerance, cystic fibrosis, Whipple’s disease, parasitic diseases, tropical sprue, intestinal disorders, and others. The Intestinal disorders segment is further classified as Celiac disease, and others.


On the basis of the treatment, the market is classified as nutritional supplements, gluten-free diet, protease and lipase supplements, antibiotics, antidiarrheal agents, anti-inflammatory drugs, and others.


On the basis of the end user, the market is segmented into pharmaceutical companies, Hospitals, Nutrition Clinics, Academic and Research Institutes, and others.


Regional Analysis:


The Americas dominate the malabsorption syndrome market owing to the rising cases of causative diseases such as lactose intolerance, diarrhea, cystic fibrosis, and others, and high healthcare expenditure. Children and adults with cystic fibrosis are at risk for low bone density, and related complications due to malabsorption of certain nutrients. According to the Cystic Fibrosis Foundation Patient Registry, more than 30,000 people are living with cystic fibrosis in the United States, and around 1,000 new cases of cystic fibrosis are diagnosed every year.


Europe holds the second position in the malabsorption syndrome market. It is expected that the support provided by the government authorities for research & development and initiatives taken to improve the reimbursement policies in healthcare is likely to drive the European market.


Asia Pacific is the fastest growing malabsorption syndrome market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare, in the years 2015-2016, the total health expenditure in Australia was USD 170.4 billion, which is recorded to be 3.6% higher than the expenditure of 2014-2015.


The Middle East & Africa holds the lowest share of the global market due to lack of technical knowledge and poor medical facilities.


Key Players:


Some of key the players in the global malabsorption syndrome market are Abbvie, Inc., Actelion Pharmaceuticals Ltd, AstraZeneca PLC, Bayer Healthcare AG, DSM, Eli Lily and Company, Gilead Sciences, GlaxoSmithKline plc, Glenmark Pharmaceuticals, KLAIRE LABORATORIES, Lupin Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, McNeil Nutritionals, National Enzyme Company, Perrigo, Pfizer, Inc., Roche, Sanofi, Vetbiochem India Private Limited, and others.



Frequently Asked Questions (FAQ) :


malabsorption syndrome market is projected to grow at an 11.0% CAGR between 2017-2023.

The Americas is expected to dominate the malabsorption syndrome market.

Rising healthcare expenditure and favorite reimbursement policies are the key factors adding to the malabsorption syndrome market growth.

Poor healthcare system and certain side effects may limit the malabsorption syndrome market growth.

Major end users of the malabsorption syndrome market include academic and research institutes, nutrition clinics, hospitals, pharmaceutical companies, and others.

Table of Contents:


Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Malabsorption Syndrome Market, by Diagnosis

6.1 Introduction

6.2 Hematologic Tests

6.2.1 Market Estimates & Forecast, 2016 – 2023

6.3 Imaging Studies

6.3.1 Market Estimates & Forecast, 2016 – 2023

6.4 Other Tests

6.4.1 Market Estimates & Forecast, 2016 – 2023

Chapter 7. Global Malabsorption Syndrome Market, by Causative Diseases

7.1 Introduction

7.2 Lactose Intolerance

7.2.1 Market Estimates & Forecast, 2017 – 2023

7.3 Cystic Fibrosis

7.3.1 Market Estimates & Forecast, 2017 – 2023

7.4 Whipple’s Disease

7.4.1 Market Estimates & Forecast, 2017 – 2023

7.5 Parasitic Diseases

7.5.1 Market Estimates & Forecast, 2017 – 2023

7.6 Tropical sprue

7.6.1 Market Estimates & Forecast, 2017 – 2023

7.7 Intestinal Disorders

7.7.1 Market Estimates & Forecast, 2017 – 2023

7.8 Others

7.8.1 Market Estimates & Forecast, 2017 – 2023

Chapter 8. Global Malabsorption Syndrome Market, by Treatment

8.1 Introduction

8.2 Nutritional Supplements

8.2.1 Market Estimates & Forecast, 2017 – 2023

8.3 Gluten-Free Diet

8.3.1 Market Estimates & Forecast, 2017 – 2023

8.4 Protease and Lipase Supplements

8.4.1 Market Estimates & Forecast, 2017 – 2023

8.5 Antibiotics

8.5.1 Market Estimates & Forecast, 2017 – 2023

8.6 Antidiarrheal Agents

8.6.1 Market Estimates & Forecast, 2017 – 2023

8.7 Anti-Inflammatory Drugs

8.7.1 Market Estimates & Forecast, 2017 – 2023

Chapter 9. Global Malabsorption Syndrome Market, by End User

9.1 Introduction

9.2 Pharmaceutical Companies

9.2.1 Market Estimates & Forecast, 2017 – 2023

9.3 Hospitals

9.3.1 Market Estimates & Forecast, 2017 – 2023

9.4 Nutrition Clinics

9.4.1 Market Estimates & Forecast, 2017 – 2023

9.5 Academic and Research Institutes

9.5.1 Market Estimates & Forecast, 2017 – 2023

9.6 Academic and Research Institutes

9.6.1 Market Estimates & Forecast, 2017 – 2023

Chapter 10. Global Malabsorption Syndrome Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 U.S.

10.2.1.1 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

Chapter 11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 Abbvie, Inc.

12.1.1 Company Overview

12.1.2 Diagnosis of Causative Agents Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 Actelion Pharmaceuticals Ltd

12.2.1 Company Overview

12.2.2 Diagnosis of Causative Agents Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 AstraZeneca PLC

12.3.1 Company Overview

12.3.2 Diagnosis of Causative Agents Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Bayer Healthcare AG

12.4.1 Company Overview

12.4.2 Diagnosis of Causative Agents/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 DSM

12.5.1 Company Overview

12.5.2 Diagnosis of Causative Agents Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 ELI LILY AND COMPANY

12.6.1 Company Overview

12.6.2 Diagnosis of Causative Agents Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 Gilead Sciences

12.7.1 Overview

12.7.2 Diagnosis of Causative Agents Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Malabsorption Syndrome Industry

Chapter 14 Appendix

LIST OF TABLES

Table 1 Malabsorption Syndrome Industry Synopsis, 2017 – 2023

Table 2 Malabsorption Syndrome Market Estimates and Forecast, 2017 – 2023, (USD Million)

Table 3 Malabsorption Syndrome Market by Region, 2017 – 2023, (USD Million)

Table 4 Malabsorption Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)

Table 5 Malabsorption Syndrome Market by Causative Diseases, 2017 – 2023, (USD Million)

Table 6 Malabsorption Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 7 Malabsorption Syndrome Market by End User, 2017 – 2023, (USD Million)

Table 8 North America Malabsorption Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)

Table 9 North America Malabsorption Syndrome Market by Causative Diseases, 2017 – 2023, (USD Million)

Table 10 North America Malabsorption Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 11 North America Malabsorption Syndrome Market by End User, 2017 – 2023, (USD Million)

Table 12 US Malabsorption Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)

Table 13 US Malabsorption Syndrome Market by Causative Diseases, 2017 – 2023, (USD Million)

Table 14 US Malabsorption Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 15 US Malabsorption Syndrome Market by End User, 2017 – 2023, (USD Million)

Table 16 Canada Malabsorption Syndrome market by Diagnosis, 2017 – 2023, (USD Million)

Table 17 Canada Malabsorption Syndrome Market by Causative Diseases, 2017 – 2023, (USD Million)

Table 18 Canada Malabsorption Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 19 Canada Malabsorption Syndrome market by End User, 2017 – 2023, (USD Million)

Table 20 South America Malabsorption Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)

Table 21 South America Malabsorption Syndrome Market by Causative Diseases, 2017 – 2023, (USD Million)

Table 22 South America Malabsorption Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 23 South America Malabsorption Syndrome Market by End User, 2017 – 2023, (USD Million)

Table 24 Europe Malabsorption Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)

Table 25 Europe Malabsorption Syndrome Market by Causative Diseases, 2017 – 2023, (USD Million)

Table 26 Europe Malabsorption Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 27 Europe Malabsorption Syndrome Market by End User, 2017 – 2023, (USD Million)

Table 28 Western Europe Malabsorption Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)

Table 29 Western Europe Malabsorption Syndrome Market by Causative Diseases, 2017 – 2023, (USD Million)

Table 30 Western Europe Malabsorption Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 31 Western Europe Malabsorption Syndrome Market by End User, 2017 – 2023, (USD Million)

Table 32 Eastern Europe Malabsorption Syndrome market by Diagnosis, 2017 – 2023, (USD Million)

Table 33 Eastern Europe Malabsorption Syndrome Market by Causative Diseases, 2017 – 2023, (USD Million)

Table 34 Eastern Europe Malabsorption Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 35 Eastern Europe Malabsorption Syndrome Market by End User, 2017 – 2023, (USD Million)

Table 36 Asia Pacific Malabsorption Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)

Table 37 Asia Pacific Malabsorption Syndrome Market by Causative Diseases, 2017 – 2023, (USD Million)

Table 38 Asia Pacific Malabsorption Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 39 Asia Pacific Malabsorption Syndrome market by End User, 2017 – 2023, (USD Million)

Table 40 The Middle East & Africa Malabsorption Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)

Table 41 The Middle East & Africa Malabsorption Syndrome Market by Causative Diseases, 2017 – 2023, (USD Million)

Table 42 The Middle East & Africa Malabsorption Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 43 The Middle East & Africa Malabsorption Syndrome market by End User, 2017 – 2023, (USD Million)
LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Malabsorption Syndrome Market

Figure 3 Segmentation Market Dynamics for Malabsorption Syndrome Market

Figure 4 Global Malabsorption Syndrome market Share, by Diagnosis 2016

Figure 5 Global Malabsorption Syndrome market Share, by Causative Diseases 2016

Figure 6 Global Malabsorption Syndrome market Share, by Treatment 2016

Figure 7 Global Malabsorption Syndrome market Share, by End User, 2016

Figure 8 Global Malabsorption Syndrome market Share, by Region, 2016

Figure 9 North America Malabsorption Syndrome market Share, by Country, 2016

Figure 10 Europe Malabsorption Syndrome market Share, by Country, 2016

Figure 11 Asia Pacific Malabsorption Syndrome market Share, by Country, 2016

Figure 12 Middle East & Africa Malabsorption Syndrome market Share, by Country, 2016

Figure 13 Global Malabsorption Syndrome market: Company Share Analysis, 2016 (%)

Figure 14 Abbvie, Inc.: Key Financials

Figure 15 Abbvie, Inc.: Segmental Revenue

Figure 16 Abbvie, Inc.: Geographical Revenue

Figure 17 Actelion Pharmaceuticals Ltd: Key Financials

Figure 18 Actelion Pharmaceuticals Ltd: Segmental Revenue

Figure 19 Actelion Pharmaceuticals Ltd: Geographical Revenue

Figure 20 AstraZeneca PLC: Key Financials

Figure 21 AstraZeneca PLC: Segmental Revenue

Figure 22 AstraZeneca PLC: Geographical Revenue

Figure 23 Bayer Healthcare AG: Key Financials

Figure 24 Bayer Healthcare AG: Segmental Revenue

Figure 25 Bayer Healthcare AG: Geographical Revenue

Figure 26 DSM: Key Financials

Figure 27 DSM: Segmental Revenue

Figure 28 DSM: Geographical Revenue

Figure 29 ELI LILY AND COMPANY: Key Financials

Figure 30 ELI LILY AND COMPANY: Segmental Revenue

Figure 31 ELI LILY AND COMPANY: Geographical Revenue

Figure 32 Gilead Sciences: Key Financials

Figure 33 Gilead Sciences: Segmental Revenue

Figure 34 Gilead Sciences: Geographical Revenue